IgG4-RD is an immune-mediated disorder. When someone has it, their immune system goes into overdrive, producing more antibodies (or immunoglobulins, hence the name) than necessary that disrupt ...

Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the ...

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the ...

High levels of IgG4, a particular type of antibody, can lead to widespread organ damage and mass growth. Early treatment with glucocorticoids or drugs that modify the immune system can help limit ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD). An ...

Immunoglobulin G4–related disease (IgG4-RD) is a rare, progressive, immune-mediated, fibroinflammatory condition. It is recognized as definite when all of the following items are present, probable ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

SAN DIEGO — Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related ... significantly reduced the risk for IgG4-related disease (IgG4-RD) flares ...

About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...

Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of historical and ...